Ultragenyx Pharmaceutical Inc. (RARE): Net Income
-$575.00M
Year ended 2025-12-31
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$575.00M | n/m | 2026-02-18, From 2025-01-01 |
| 2024-12-31 | -$569.00M | n/m | 2026-02-18, From 2024-01-01 |
| 2023-12-31 | -$607.00M | n/m | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | -$707.42M | n/m | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | -$454.02M | n/m | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | -$186.57M | n/m | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | -$402.73M | n/m | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | -$197.61M | n/m | 2021-02-12, From 2018-01-01 |
| 2017-12-31 | -$302.14M | n/m | 2020-02-14, From 2017-01-01 |
| 2016-12-31 | -$245.87M | n/m | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | -$145.62M | n/m | 2018-02-21, From 2015-01-01 |
| 2014-12-31 | -$59.80M | n/m | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | -$35.07M | n/m | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | -$16.33M | n/a | 2015-03-27, From 2012-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$575.00M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $59.01M | n/m |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$183.17M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | -$38.55M | n/m |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $98.09M | -38.5% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $7.03M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $447.18M | n/m |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $52.60M | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$225.68M | n/m |
Compare RARE, KNSA, AXSM, SUPN side by side · Screen every company in Pharmaceutical Preparations ↗